Case Report

Transient Hypoparathyroidism in Diabetic Ketoacidosis

Abstract

Introduction: Diabetic ketoacidosis patients frequently develop a constellation of electrolyte disorders. These patients are marked by potassium-, magnesium- and phosphate-depleted, but hypocalcemia due to transient hypoparathyroidism was seldom reported previously.

Methods: We describe the clinical history, physical examination findings and laboratory values of the patient and briefly review the relevant literature.

Result: A 43-year-old man with a history of diabetes mellitus presented with vomiting, diarrhea and fatigue for 2 days and his laboratory tests showed high serum glucose and diabetic ketoacidosis. CT scan of the abdomen showed no abnormality. Intravenous fluid resuscitation and continuous insulin infusion was initiated. Omeprazole was started for possible gastrointestinal hemorrhage. Hypocalcemia, hypophosphatemia, relative hypomagnesemia and transient hypoparathyroidism occurred in the recovering process of diabetic ketoacidosis. There was neither tetany nor spasm in this patient. Two days after the cessation of omeprazole, his serum total calcium, serum phosphate and PTH all returned to normal range.

Conclusion: Physicians should alert transient hypoparathyroidism in diabetic ketoacidosis patients, especially those treated with proton pump inhibitors.

Abbreviations

DKA: Diabetic Ketoacidosis; PPI: Proton-pump Inhibitor; PTH: Parathyroid Hormone; HHS: Hyperglycemic Nonketotic Hyperosmolar Syndrome

Introduction

Diabetic ketoacidosis (DKA) is characterized by hyperglycemia, metabolic acidosis and increased ketones, caused by starvation of any cause in conjunction with an inter-current illness and has been described mainly in type 1 diabetes but also in type 2 and gestational diabetes. Diabetic patients frequently develop a constellation of electrolyte disorders. These patients are often potassium-, magnesium- and phosphate-depleted, especially in the context of diabetic ketoacidosis or hyperglycemic nonketotic hyperosmolar syndrome (HHS). But hypocalcemia due to transient hypoparathyroidism was seldom reported previously. Transient impaired secretion of parathyroid hormone (PTH) from the parathyroid glands can lead to functional hypoparathyroidism, which is commonly seen in profound hypomagnesemia. In this proton-pump era, proton-pump inhibitor (PPI) is commonly used in DKA patients when their first onset is digestive symptom. We report one case of hypocalcemia, hypophosphatemia and transient hypoparathyroidism in diabetic ketoacidosis possibly associated with the use of PPI.

Case Presentation

A 43-year-old man presented to the emergency room with vomiting, diarrhea and fatigue for 2 days. He passed liquid stool more than 30 times a day and only had gruel and soft drinks. His vomit sample contained blood. His medical reviews showed he was diagnosed as diabetes mellitus for 11 years with first onset of thirsty, polydipsia and polyuria. He was prescribed with insulin on diagnosis and in poor treatment compliance. He suffered from diabetic ketoacidosis and acute pancreatitis 2 years ago. Laboratory investigation showed the following: serum glucose 36.2 mmol/L, total cholesterol 6.93 mmol/L, total triglyceride 2.81 mmol/L, low density lipoprotein cholesterol 4.06 mmol/L, serum-α-amylase 213 U/L. On admission, his serum total calcium and magnesium were both within the normal range (Ca²⁺ 2.26 mmol/L, reference range 2.00–2.75 mmol/L; Mg²⁺ 1.26 mmol/L, reference range 0.78–1.27 mmol/L), his serum phosphate was a little higher than the upper limit of normal range (1.84 mmol/L, reference range 0.81–1.78 mmol/L). Arterial blood gases demonstrated metabolic acidosis (pH 6.98, HCO₃⁻ 3 mmol/L) with negative lactic acid. Further work-up revealed ketonuria (15 mmol/L). His HbA1c was 13.9%. CT scan of the abdomen showed no abnormality. He was diagnosed as diabetic ketoacidosis. Intravenous fluid resuscitation and continuous insulin infusion was initiated. Omeprazole was started for possible upper gastrointestinal hemorrhage. After about six hours of initial fluid resuscitation and continuous insulin infusion, hypocalcemia became obvious and calcium supplement was added into the fluid. One day after intensive fluid resuscitation, pH and bicarbonate level returned to normal range. Urinalysis showed no ketonuria. Serum PTH was severely below the normal range with hypophosphatemia and a decrease of serum magnesium. Standard meal test showed absolute insulin/c-peptide deficiency. He was finally diagnosed as type 1 diabetes mellitus and switched to subcutaneous lispro insulin and glargine insulin treatment. On the four day after admission, fecal occult blood was negative and omeprazole was stopped. We intensively tested the serum electrolyte. On the sixth day after admission, his serum total calcium, serum phosphate and
PTH all returned to normal range. There was neither tetany nor spasms in this patient. Hypocalcemia, hypophosphatemia, relative hypomagnesemia and transient hypoparathyroidism occurred in the recovering process of diabetic ketoacidosis (Table 1). Unfortunately we didn’t monitor the serum magnesium level as frequently as we monitored the serum calcium level, so we were unable to figure out the lowest level of serum magnesium. But a U-shape of the serum magnesium level could be predicted based on Table 1.

### Discussion

Significant Ca²⁺ and Mg²⁺ losses have been demonstrated during ketoacidosis and the first hours of recovery. Negative Ca²⁺ and Mg²⁺ balance occurs immediately following insulin withdrawal, progresses with acidosis and continues through the first few days of recovery. Martin et al measured serum and urine Ca²⁺ and Mg²⁺ concentrations in 29 patients with ketoacidosis and found that 28% were hypocalcemic when first seen [1]. Balance studies demonstrated that with standard treatment, large amounts of both Ca²⁺ and Mg²⁺ continued to be lost through the urine. After 12h of therapy, 73% of the patients were hypocalcemic and 55% were hypomagnemic. Since hypocalcemic states are associated with defective pancreatic β-cell insulin release [2], it is possible that the impairment of residual insulin secretion that occurs after ketoacidosis is in part secondary to prolonged negative Ca²⁺ balance. The etiology of Ca²⁺ and Mg²⁺ loss is thought to be osmotic diuresis and the increased mobilization from bone of both ions induced by acidosis [3,4]. Glycosuria, without acidosis, has been shown to triple urinary Ca²⁺ and double urinary Mg²⁺ excretion [5]. Acidosis might also inhibit renal tubular reabsorption of Ca²⁺ ions. Administration of insulin, 0.1U/kg, has been shown to cause small increase in urinary Mg²⁺ excretion [6]. When Mg²⁺ depletion becomes severe, a reversible state of hypoparathyroidism can occur. Hypomagnesemia appears to inhibit both synthesis and releases of PTH and also decreases peripheral responsiveness to PTH [7]. There is evidence that diabetic patients are relatively hypoparathyroid [8]. In fact, a mild shift downwards in the set-point for PTH secretion in patients with insulin-dependent diabetes mellitus as well as a diminished parathyroid gland responsiveness to hypocalcemia in uremic diabetic patients have been reported [9,10]. The state of hypoparathyroidism would abolish the homeostatic Ca²⁺ control mechanisms that normally maintain serum Ca²⁺ concentrations despite continued loss. The patient in our study had evidence of impaired parathyroid responsiveness.

Decompensated diabetes mellitus with ketoacidosis is associated with excessive phosphate loss due to osmotic diuresis. Despite phosphate depletion, the serum phosphate concentration at presentation is usually normal or even high, because both insulin deficiency and metabolic acidosis cause a shift of phosphate out of cells [11]. Administration of insulin and fluids, and correction of ketoacidosis may reveal phosphate deficiency and cause a sharp decrease in plasma phosphate concentration due to intracellular shift [12]. The routine administration of phosphate during treatment of DKA and HHS is not recommended since randomized trials failed to show any clinical benefit from phosphate administration [12-15]. What is more, correction of hypophosphatemia may have adverse effects, such as hypocalemia and hypomagnesemia [12,13,16]. Careful phosphate replacement is required in patients with severe hypophosphatemia of less than 1.0 mg/dl (0.32mmol/L) and in patients who develop cardiac dysfunction, hemolytic anemia, or respiratory depression [13,17].

A number of cases of PPI therapy causing hypomagnesemia and hypomagnesemic hypoparathyroidism are reported in literature [18,19]. PPI-induced hypocalcemia maybe due to hypomagnesemia, which may cause a functional hypoparathyroidism, resulting in suppressed parathyroid hormone secretion [20]. It is usually believed that hypomagnesemic hypoparathyroidism does not respond to calcium supplementation until magnesium levels are replenished, but recent case reports show the serum calcium levels normalized before magnesium supplementation was introduced. This sequence of events differed from the typical pattern, which might explain why hypomagnesemic hypoparathyroidism has been unrecognized.
Conclusion

The clinical implication of this case is important. Physicians should alert transient hypoparathyroidism in diabetic ketoacidosis patients. We suggest that magnesium and calcium levels should be measured in diabetic ketoacidosis patients especially those treated with proton-pump inhibitors.

Conflict of Interest

The authors have no multiplicity of interest to disclose.

References

1. Martin HE, Smith K, Wilson ML (1958) The fluid and electrolyte therapy of severe diabetic acidosis and ketosis. Am J Med 24: 376-389.
2. Yasuda K, Hurukawa Y, Okuyama M, Kikuchi M, Yoshinaga K (1975) Glucose tolerance and insulin secretion in patients with parathyroid disorders—effect of calcium on insulin release. N Engl J Med 292: 501-504.
3. Wacker WE, Parisi AF (1968) Magnesium metabolism. N Engl J Med 278: 712-717.
4. Butler AM (1950) Diabetic coma. N Engl J Med 243: 648-659.
5. al-Ghamdi SM, Cameron EC, Sutton RA (1994) Magnesium deficiency: pathophysiologic and clinical overview. Am J Kidney Dis 24: 737-752.
6. Lindeman RD (1969) Influence of various nutrient and hormones on urinary divalent cation excretion. Ann NY Acad Sci 162: 802-809.
7. Rude RK, Oldham SB, Sharp CF Jr, Singer FR (1978) Parathyroid hormone secretion in magnesium deficiency. J Clin Endocrinol Metab 47: 800-806.
8. McNair P, Christsensen MS, Madbsod S, Christiansen C, Transbal I (1981) Hypoparathyroidism in diabetes mellitus. Acta Endocrinol (Copenh) 96: 81-86.
9. Schwarz P, Sørensen HA, Momsen G, Friis T, Transbal I, et al. (1992) Hypocalcemia and parathyroid hormone responsiveness in diabetes mellitus: a tri-sodium-citrate clamp study. Acta Endocrinol (Copenh) 126: 285-293.
10. Heidbreder E, Götz R, Schafferhans K, Heidiland A (1986) Diminished parathyroid gland responsiveness to hypocalcemia in diabetic patients with uremia. Nephron 42: 285-289.
11. Kebler R, McDonald FD, Cadnapaphornchai P (1985) Dynamic changes in serum phosphorus levels in diabetic ketoacidosis. Am J Med 79: 577-578.
12. Fisher JN, Kitabchi AE (1983) A randomized study of phosphatetheory in the treatment of diabetic ketoacidosis. J Clin Endocrinol Metab 57: 177-180.
13. Kitabchi AE, Umpierrez GE, Murphy MB, Kreisberg RA (2006) Hyperglycemic crises in adult patients with diabetes: a consensus statement from the American Diabetes Association. Diabetes Care 29: 2739-2748.
14. Keller U, Berger W (1980) Prevention of hypophosphatemia by phosphate infusion during treatment of diabetic ketoacidosis and hyperosmolar coma. Diabetes 29: 87-95.
15. Wilson HK, Keuer SP, Lea AS, Boyd AE, Eknoyan G (1982) Phosphate therapy in diabetic ketoacidosis. Arch Intern Med 142: 517-520.
16. Winter RJ, Harris CJ, Phillips LS, Green OC (1979) Diabetic ketoacidosis. Induction of hypocalcemia and hypomagnesemia by phosphate therapy. Am J Med 67: 897-900.
17. Evans KJ, Thompson J, Spratt SE, Lien LF, Vorderstrasse A (2014) The implementation and evaluation of an evidence-based protocol to treat diabetic ketoacidosis: a quality improvement study. Adv Emerg Nurs J 36: 189-198.
18. Epstein M, McGrath S, Law F (2006) Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med 355: 1834-1836.
19. François M, Lévy-Bohbot N, Caron J, Durlach V (2008) Chronic use of proton-pump inhibitors associated with giardiasis: A rare cause of hypomagnesemic hypoparathyroidism? Ann Endocrinol (Paris) 69: 446-448.
20. Rude RK, Oldham SB, Singer FR (1976) Functional hypoparathyroidism and parathyroid hormone end-organ resistance in human magnesium deficiency. Clin Endocrinol (Oxf) 5: 209-224.